pegcantratinib + calcipotriene

**pegcantratinib + calcipotriene** is an investigational combination topical therapy comprised of **pegcantratinib** (a tropomyosin receptor kinase inhibitor) and **calcipotriene** (a synthetic vitamin D3 analog)[1][2]. Calcipotriene slows the excessive proliferation of skin cells by binding to the vitamin D receptor and modulating gene expression involved in cell growth and differentiation[1][2][4][6]. Pegcantratinib is designed to inhibit tropomyosin receptor kinase proteins, which are implicated in the pathophysiology of certain skin diseases, particularly those with abnormal cell signaling. The combination is intended for dermatological use, likely targeting conditions such as *palmoplantar keratoderma* and/or *psoriasis* where both excessive skin cell proliferation and abnormal signaling contribute to disease pathology. The mechanism of action combines a kinase inhibitor targeting cell signaling pathways (pegcantratinib) with a differentiating agent (calcipotriene), potentially offering synergistic effects for disease control. Clinical development details for this specific combination are currently limited.